Skip to main content
. 2000 Sep 12;97(20):10990–10995. doi: 10.1073/pnas.180329197

Table 2.

Baseline characteristics of the patients enrolled in the phase II clinical study

Age
 Median 70 years
 Range 49–86 years
PSA
 Median 13.7 ng/ml
 Range 1.0–919.6 ng/ml
Androgen dependent 12/41 (29%)
Androgen independent 29/41 (71%)
Metastases 16/41 (39%)
Bidimensionally measurable disease 0/41 (0%)
Gleason sum
 4–6 4/41 (11%)
 7 14/41 (34%)
 8–10 23/41 (55%)